Safe Supply Streaming Co. Ltd. Completes Reverse Take-Over Transaction and Prepares for Listing on the Canadian Securities Exchange

Toronto, Ontario–(Newsfile Corp. – September 22, 2023) – Safe Supply Streaming Co. Ltd. (formerly Origin Therapeutics Inc.) (“Safe Supply” or the “Company“) is pleased to announce that it has completed its previously announced reverse take-over transaction (the “Transaction“). The Transaction was completed by way of a three-cornered amalgamation under the Canada Business Corporations Act, whereby the Company was amalgamated with the predecessor entity operating as Safe Supply Streaming Co. Ltd (“SSSC“).

Safe Supply is the first company that was created to invest in and incubate companies at the forefront of the third wave of drug policy reform.

Safe Supply anticipates that the common shares of the Company (the “Shares“) will commence trading on the Canadian Securities Exchange (the “CSE“) on or about September 26, 2023, under the symbol “SPLY“, subject to customary conditions, including the final approval of the CSE.

“This is a watershed moment for the safe supply ecosystem and the third wave of drug policy reform,” said Bill Panagiotakapoulos, Safe Supply’s CEO. “Jurisdictions around the world are descheduling, rescheduling and legalizing drugs, which is not only smart policy, it is creating a massive investment opportunity. Our public listing on the CSE gives investors a means to gain exposure to this movement, as we execute on our strategy to invest in and incubate companies at the forefront of this opportunity, and help to bring a responsible end to the war on drugs.”

In connection with the Closing:

  • The management and board of directors of the Company was reconstituted to consist of Bill Panagiotakopoulos, Setti Coscarella, Najla Guthrie, Frank Selvetti and Dr. James Obaji. The officers of the Company are Bill Panagiotakapoulos (CEO), Setti Coscarella (VP, Corporate Development) and David Bhumgara (CFO).
  • An aggregate of 5,965,000 subscription receipts of SSSC, which were issued pursuant to the previously announced concurrent private placement of SSSC for aggregate gross proceeds of $2,386,000 (the “Concurrent Financing“), were converted for no additional consideration into an aggregate of 5,965,000 Shares.
  • Shareholders of SSSC received one Share for every common share of SSSC held.

Following closing of the Transaction, the Company has 70,217,750 Shares outstanding, of which 14,140,750 Shares are held by the shareholders of Origin Therapeutics Inc. prior to the completion of the Transaction (and after a 4:1 consolidation of common shares of Origin Therapeutics Inc.) and 56,077,000 Shares (inclusive of subscribers in the Concurrent Financing) are held by the former shareholders of SSSC. In addition, an aggregate of 375,000 Shares are issuable upon the exercise of stock options of the Company and an aggregate of 434,750 Shares are issuable upon the exercise of compensation options or warrants granted to brokers, finders or agents in connection with the Concurrent Financing.

Additional information regarding the business of the Company and the biographical details of management and the board of directors can be found in the Company’s CSE Form 2A Listing Statement, which will be filed on SEDAR prior to the commencement of trading on the CSE.

About Safe Supply

With a mission to help bring a responsible end to the war on drugs, Safe Supply Streaming Co. Ltd. is investing in and incubating companies at the forefront of the third wave of drug policy reform. As jurisdictions around the world move to decriminalize, regulate and legalize drugs, Safe Supply is investing in the infrastructure necessary to support the transition. From developing the facilities to analyze, manufacture and distribute psychoactive compounds including the coca plant, to investing in the research and innovation to harness the potential, and minimize the harm, of these medicines, to constructing the clinical infrastructure to ensure safe and responsible access and treatment, Safe Supply is building a platform of tightly woven companies that will help save millions of lives and build a safer, healthier post-war on drugs worlds.

Learn more at www.safesupply.com and follow Safe Supply on LinkedIn, Twitter, and Instagram.

For Further Information:

Bill Panagiotakopoulos
Chief Executive Officer and Director
Safe Supply Streaming Co. Ltd.
[email protected]

Media contacts:

McKenna Miller
KCSA Strategic Communications
[email protected]

Forward-Looking Information and Statements

Certain statements in this news release related to Safe Supply are forward-looking statements and are prospective in nature, including but not limited to the express or implied statements and assumptions regarding the intention of Safe Supply to list the common shares on the Exchange and the timing thereof. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In particular, there is no guarantee that the Corporation will successfully list the common shares on the Exchange. These forward-looking statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “will” or “continue”, or the negative thereof or similar variations. There are numerous risks and uncertainties that could cause actual results and Safe Supply’s plans and objectives to differ materially from those expressed in the forward-looking statements, including but not limited to adverse market conditions and risks inherent in the Safe Supply’s business in general. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this news release. Except as required by applicable law, Safe Supply does not intend to update these forward-looking statements.

The CSE has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

None of the securities to be issued in connection with the Transaction have been, or will be, registered under the United States Securities Act of 1933, as amended (the “1933 Act“), or any state securities laws, and may not be offered or sold within the United States or to any U.S. Person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available. This press release does not constitute an offer to sell or a solicitation of an offer to sell any securities in any jurisdiction where such offer or solicitation would be unlawful, including the United States.


In accordance with an executed agreement between The Dales Report and Safe Supply Streaming, The Dales Report is engaged with the aforementioned on a 4-month contract for $9,000 per Month + 20,000 shares in the company, with the purpose of publicly disseminating information pertaining to Safe Supply Streaming via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More